Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

NCT02453555 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

275

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Linagliptin
DRUG: Empagliflozin placebo + linagliptin placebo low dose
DRUG: Empagliflozin + linagliptin low dose
DRUG: Linagliptin placebo
DRUG: Empagliflozin + linagliptin high dose
DRUG: Empa + lina highdose placebo

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]